Received Feb 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Patient was given influenza vaccine at 4 months of age; This non-serious case was reported by a other health professional and described the occurrence of inappropriate age at vaccine administration in a 4-month-old male patient who received Flu Seasonal TIV Quebec (FluLaval 2024-2025 season) for prophylaxis. Concurrent medical conditions included bronchiolitis. Concomitant products included salbutamol sulfate (Albuterol Sulfate). On 05-FEB-2025, the patient received FluLaval 2024-2025 season .5 ml. On 05-FEB-2025, an unknown time after receiving FluLaval 2024-2025 season, the patient experienced inappropriate age at vaccine administration (Verbatim: Patient was given influenza vaccine at 4 months of age). The outcome of the inappropriate age at vaccine administration was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 05-FEB-2025 The reporter reported that the 4 months old patient received Flulaval vaccine which led to, inappropriate age at vaccine administration. The expiry date of Flulaval vaccine was unknown. The patient received Albuterol sulfate for bronchiolitis.
Bronchiolitis
ALBUTEROL SULFATE